CLIMB BIO INC (CLYM) Stock News
NASDAQ:CLYM - Nasdaq - US28658R1068 - Common Stock - Currency: USD
CLYM Latest News, Press Relases and Analysis
Friday's after hours session: top gainers and losers
Discover the top movers in Friday's after-hours session and stay informed about the post-market dynamics.
Exec Edge Launches Research Coverage with Initiation Notes on FLD, CLYM, STKS, REX
By Exec Edge Editorial Staff Exec Edge today announced the formal launch of Exec Edge Research, a platform that will publish detailed initiation notes along with quarterly updates. Exec Edge Research is a highly specialized platform focused on US and global equities, with an emphasis on fundamental analysis. Our first round of initiation reports includes […]
Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors
Appointments Include Industry Veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo as Independent Directors
Climb Bio to Present at the 24th Annual Needham Virtual Healthcare Conference
Climb Bio Fueled Up with Cash, Poised for More Milestones in ’25 – Quarterly Update Report
Visit Exec Edge Research for Full Report By Exec Edge Research Climb Bio, Inc. (Nasdaq: CLYM) reported full-year results, highlighting a healthy cash cushion and several milestones for investors to watch closely during the remainder of 2025. As we highlighted in our 66-page initiation report last week (download here), CLYM’s lead asset is Budoprutug, an […]
Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates
Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates
Received Clearance from the U.S. Food and Drug Administration (FDA) for Clinical Trials of Budoprutug in Primary Membranous Nephropathy (pMN), Immune...
Climb Bio: Meet The Newest Star in Autoimmune Disease Treatment – Initiation Report
By Rayk Riechmann As one of the brightest emerging biotechnology companies, Climb Bio Inc. (NASDAQ: CLYM) aims to improve the efficacy of autoimmune disease treatment. With its recently acquired lead asset, Budoprutug, and exclusively licensed Anti-APRIL antibody, CLYM116, the innovative biotech play is positioned to pull ahead of the pack. We expect 2025 to be […]
Climb Bio to Present at Upcoming Investor Conferences
Climb Bio Appoints Perrin Wilson, Ph.D., as Chief Business Officer
Climb Bio Appoints Perrin Wilson, Ph.D., as Chief Business Officer
WELLESLEY HILLS, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) announced today the appointment of Perrin Wilson, Ph.D. as Chief...
Climb Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Climb Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
WELLESLEY, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced that members of its executive team will participate at...
Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy
Transaction Expands Climb Bio’s Pipeline of B-cell Targeted Therapeutics to Address Immune-mediated Diseases New Program is a Highly Potent,...
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Climb Bio, Inc. (NASDAQ: CLYM)
/PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Climb Bio, Inc. (NASDAQ: CLYM) on behalf of the company's shareholders. The...
Climb Bio to be Added to the Nasdaq Biotechnology Index
WELLESLEY HILLS, Mass., Dec. 19, 2024 (GLOBE NEWSWIRE) -- December 19, 2024 – Climb Bio, Inc. (Nasdaq: CLYM) today announced that the company will be...
Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights
Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights
Appointed Douglas Williams, Ph.D. as Chair of the Board of Directors FDA Clearance of Investigational New Drug Application (IND) for systemic lupus...
Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board
Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board
WELLESLEY, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced the appointment of Douglas E. Williams, Ph.D., as...
Climb Bio to Present at Upcoming Investor Conferences
Climb Bio to Provide Budoprutug Development Strategy and Corporate Update at Virtual Investor Event
Climb Bio to Provide Budoprutug Development Strategy and Corporate Update at Virtual Investor Event
Completes Transition to Immune-Mediated Disease Focused Company Highlights Additional Data from Phase 1b Primary Membranous Nephropathy (pMN) Study...
Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024
Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024
WELLESLEY, Mass., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced that it will present data at the American Society of...
Climb Bio to Present at William Blair’s Upcoming Conference Event on Transforming Autoimmune Diseases by Targeting CD19
Climb Bio to Present at William Blair’s Upcoming Conference Event on Transforming Autoimmune Diseases by Targeting CD19
WELLESLEY, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced today it will present and host investor meetings at William...
Climb Bio to Host Virtual Investor Event on October 15, 2024
Climb Bio to Host Virtual Investor Event on October 15, 2024
WELLESLEY, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced today it will host a virtual investor day on October 15,...